MARATTO

article · Zagazig University Medical Journal

Diagnostic significance of latent membrane protein 1 (LMP-1), EMA, CD45, CD20 and CD3 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma

Abstract

Background: Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma which differ from other head and neck cancers and linked to the Epstein Barr virus (EBV) and its encoded oncoproteins, such as EBNA1 and LMP1.These viral oncogenes have been found to be an important factor in its pathogenesis. Objectives: To diagnose NPC and differentiate it from lymphoma, also to assess the expression pattern of LMP1 in the different histological types of NPC in a sample of the Egyptian population and to introduce serologic methods for screening and early detection of NPC. Results: Eighty-eight trans-nasal biopsies were examined. Carcinoma of the nasopharynx was detected in 79 of them. Of NPC patients 74/79 (93.6 %) showed positive test against IgA/ VCA. Late Membrane Protein was detected in 37/43(74 %) of cases of NPC tumor. Using histopathology as the gold standard for NPC, the sensitivity and specificity was 84% and 86% respectively with highly significant (p = 0.018). Epithelial membrane antigen was detected in 32/43 (64 %) NPC biopsies, the sensitivity and specificity was 72 % and 86 % respectively (p= 0.018). CD45 was positive in all 50 biopsies in the background leukocytes and negative in the tumor cells. Conclusion; Type III undifferentiated carcinoma is the commonest type of NPC. The antibodies to EBV-VCA IgA are of diagnostic value in early detection and are recommended for NPC screening at the population level.

Research topics

  • Viral-associated cancers and disorders

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/zumj.2024.282862.3335

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.